tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ashwani Verma, 57 are a BUY (70.37%), 20 are a HOLD (24.69%), 4 are a SELL (4.94%).
Analyst Ashwani Verma, currently employed at UBS, carries an average stock price target met ratio of 59.48% that have a potential upside of 23.21% achieved within 143 days.
Ashwani Verma’s has documented 162 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 04-Apr-2025.
Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for ACLX (ARCELLX) at 10/17/2023. The price target of $52 was fulfilled within 30 days with a profit of $16.84 (47.9%) receiving and performance score of 15.97.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$132
$0.13 (0.10%)
$132
16 days ago
(02-Apr-2025)
28/30 (93.33%)
$0.13 (0.10%)
476
Buy
$132
$0.13 (0.10%)
$100
1 months 25 days ago
(24-Feb-2025)
10/11 (90.91%)
$3.46 (2.69%)
292
Hold
$100
1 months 28 days ago
(21-Feb-2025)
21/22 (95.45%)
$-27.19 (-21.38%)
170
Hold
$132
$0.13 (0.10%)
$113
2 months 18 days ago
(31-Jan-2025)
12/13 (92.31%)
$4.92 (3.87%)
738
Hold
$132
$0.13 (0.10%)
$108
2 months 27 days ago
(22-Jan-2025)
24/25 (96%)
$4.85 (3.81%)
233
Which stock is Ashwani Verma is most bullish on?
Which stock is Ashwani Verma is most reserved on?
What Year was the first public recommendation made by Ashwani Verma?
